OncoGenex to Present at Leerink Global Healthcare Investor Conference

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 6, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 8:50 a.m. ET at the Waldorf Astoria Hotel in New York City.

A live audio webcast can be accessed through the Investor Relations page of the OncoGenex website at www.oncogenex.com. The webcast replay will be archived for 60 days.

Highlights from the presentation can be followed on the new OncoGenex Investor Relations Twitter account at: http://twitter.com/@OncoGenex_IR.

ABOUT ONCOGENEX
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

SOURCE OncoGenex Pharmaceuticals, Inc.



RELATED LINKS
http://www.OncoGenex.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.